Ferran Sanz, Director of GRIB, full professor with tenure of Preventive Medicine and Public Health Area (Biostadistics and Biomedical Informatics) at Pompeu Fabra University has been nominated as member of Scientific Committee of the Innovative Medicines Initiative (IMI).
IMI is a unique Public-Private Partnership (PPP) between the pharmaceutical industry represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the European Communities represented by the European Commission. IMI grew out of the European Technology Platform on Innovative Medicines. The platform was launched under the 6th Framework Programme for Research (FP6) as a gathering of stakeholders, led by the pharmaceutical industry.
The IMI Joint Undertaking between EFPIA and the European Commission, formally set up by the Council decision, is the legal entity responsible for implementing the IMI. The governance structure of IMI comprises the Joint Undertaking consisting of three bodies, the IMI Governing Board, the IMI Executive Director with its office and the IMI Scientific Committee, as well as the IMI Member States Group and the IMI Stakeholder Forum.